☆ 4.3 Letter

Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosis

ERJ OPEN RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Letter Critical Care Medicine

BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study

Philip L. Molyneaux et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Immunology

Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype

Emily Fraser et al.

Summary: Monocytes in idiopathic pulmonary fibrosis (IPF) patients exhibit a distinct immunophenotype from age-matched controls, with an activated type I interferon pathway that may contribute to driving chronic inflammation and fibrosis. These findings strengthen the potential role of monocytes in the pathogenesis of IPF.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response

Willis S. Bowman et al.

Summary: Interstitial lung disease (ILD) is a group of diverse lung disorders that can lead to irreversible pulmonary fibrosis. While idiopathic pulmonary fibrosis (IPF) is a common subtype, other ILD patients may develop a progressive fibrosing phenotype. Biomarker investigation has identified molecular markers that can predict disease endpoints, suggesting potential for biomarker implementation in ILD management.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Editorial Material Respiratory System

A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages

Nikita Joshi et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Review Immunology

Emerging roles of IL-34 in health and disease

Iva Lelios et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Review Respiratory System

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review

Yet H. Khor et al.

EUROPEAN RESPIRATORY REVIEW (2020)

Add to Collection

Review Medicine, Research & Experimental

Management of Fibrosing Interstitial Lung Diseases

Toby M. Maher et al.

ADVANCES IN THERAPY (2019)

Add to Collection

Article Respiratory System

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages

Lydia Meziani et al.

EUROPEAN RESPIRATORY JOURNAL (2018)

Add to Collection

Article Critical Care Medicine

Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Respiratory System

Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis

Argyris Tzouvelekis et al.

RESPIROLOGY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?

Adam J. Byrne et al.

TRENDS IN MOLECULAR MEDICINE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis

Nicoline M. Korthagen et al.

RESPIRATORY MEDICINE (2011)

Add to Collection

Article Critical Care Medicine

Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis

Christopher P. Baran et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)

Add to Collection

Article Critical Care Medicine

Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent

H Takahashi et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.